ESMO Magnitude of Clinical Benefit Scale: Scale Evaluation Forms v1.0 & v1.1

The ESMO Magnitude of Clinical Benefit Scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.

The ESMO-MCBS v1.0 was launched in May 2015 and in September 2017 an updated version ESMO-MCBS v1.1 was launched.  The forms and instructions for both versions can be found by selecting below: 

Scale Evaluation Forms 1.0  Scale Evaluation Forms 1.1

The highest grade of the ESMO-MCBS is A in the curative setting and this is restricted to new curative treatments with a grade B also to be considered to trigger rapid reimbursement.

For non-curative indications 5 is the highest possible grade with 4 also to be considered to trigger rapid consideration for reimbursement.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings